Immediate Impact

5 hit
Sub-graph 1 of 3

Citing Papers

Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations
2021 Hit
Molecular therapies for HCC: Looking outside the box
2020 Hit

Works of Kohei Ishikawa being referenced

A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
2018
Rankless by CCL
2026